Effect of argatroban on laboratory measurement of fibrinogen activity in ex vivo samples - Potential for errors in clinical decision-making
Int J Lab Hematol
.
2023 Oct;45(5):781-783.
doi: 10.1111/ijlh.14061.
Epub 2023 Mar 20.
Authors
Sean Platton
1
,
Charlotte Hill
2
,
Will Lester
3
,
Nada Yartey
4
5
,
Peter MacCallum
4
6
Affiliations
1
Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London, UK.
2
Haemostasis Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
3
Haemophilia Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
4
Department of Haematology, Barts Health NHS Trust, London, UK.
5
NHS East and South East London Pathology Partnership, Barts Health NHS Trust, London, UK.
6
Wolfson Institute of Population Health, Queen Mary University of London, London, UK.
PMID:
36941797
DOI:
10.1111/ijlh.14061
No abstract available
Publication types
Letter
Comment
MeSH terms
Anticoagulants* / pharmacology
Blood Coagulation*
Clinical Decision-Making
Fibrinogen
Heparin
Humans
Pipecolic Acids / pharmacology
Substances
argatroban
Anticoagulants
Pipecolic Acids
Fibrinogen
Heparin